KSE - Delayed Quote KRW

Chong Kun Dang Holdings Corp. (001630.KS)

50,100.00
+700.00
+(1.42%)
As of 12:01:15 PM GMT+9. Market Open.
Loading Chart for 001630.KS
  • Previous Close 49,400.00
  • Open 49,400.00
  • Bid 50,000.00 x --
  • Ask 50,100.00 x --
  • Day's Range 49,250.00 - 50,100.00
  • 52 Week Range 40,700.00 - 61,500.00
  • Volume 2,089
  • Avg. Volume 4,904
  • Market Cap (intraday) 238.504B
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Aug 12, 2025 - Aug 18, 2025
  • Forward Dividend & Yield 1,400.00 (2.83%)
  • Ex-Dividend Date Dec 27, 2024
  • 1y Target Est 50,000.00

Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. The company was founded in 1941 and is based in Seoul, South Korea.

www.ckd-holdings.com/company/summary.do

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 001630.KS

View More

Performance Overview: 001630.KS

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

001630.KS
5.03%
KOSPI Composite Index (^KS11)
9.74%

1-Year Return

001630.KS
14.39%
KOSPI Composite Index (^KS11)
3.56%

3-Year Return

001630.KS
16.11%
KOSPI Composite Index (^KS11)
1.11%

5-Year Return

001630.KS
57.28%
KOSPI Composite Index (^KS11)
36.62%

Compare To: 001630.KS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 001630.KS

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    235.17B

  • Enterprise Value

    653.71B

  • Trailing P/E

    7.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.25

  • Price/Book (mrq)

    0.40

  • Enterprise Value/Revenue

    0.68

  • Enterprise Value/EBITDA

    6.27

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.51%

  • Return on Assets (ttm)

    1.50%

  • Return on Equity (ttm)

    4.82%

  • Revenue (ttm)

    957.75B

  • Net Income Avi to Common (ttm)

    33.6B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    61.12B

  • Total Debt/Equity (mrq)

    56.45%

  • Levered Free Cash Flow (ttm)

    -26.53B

Research Analysis: 001630.KS

View More

Company Insights: 001630.KS

Research Reports: 001630.KS

View More

People Also Watch